Orthostatic intolerance (dizziness, lightheadedness)

Start here: when standing drains the brain

Every time you stand, gravity pulls a large cup of blood downward into your legs and abdomen. A healthy body reacts in seconds, tightening those vessels and nudging the heart so the brain never notices. In orthostatic intolerance that correction falls short, the brain runs briefly low on blood, and you feel it as dizziness, fog, visual graying, or the sense that you might go down.

This is the broader problem that postural orthostatic tachycardia syndrome sits inside. You can have the dizziness of orthostatic intolerance without meeting the heart-rate threshold for POTS, and the management overlaps heavily either way. The symptom is the brain protesting a supply problem, not a sign that anything is wrong with your mind.

Why the brain comes up short

A leading reason is too little blood in circulation. Careful measurements in postural tachycardia have repeatedly found a blood-volume deficit, which means there is less fluid in the system to send upward when you rise.¹ A newer, more precise method that has people rebreathe a trace gas confirmed the same shortfall.²

The second reason is poor vessel control. If the small nerves and reflexes that should clamp leg vessels on standing underperform, blood pools low and the brain is shortchanged regardless of how much fluid is in the tank. Most people have some mix of the two, which is why treatment works best when it both fills the tank and supports the squeeze.

blood-volume deficit measuredvessel-control data thinnerusually a mix of causes

The serotonin and platelet color

Two smaller threads add detail. One cohort tied postural tachycardia to a platelet storage problem, a quirk in how platelets hold their chemical cargo.³ Separately, reduced serotonin has been reported after viral infection and could disturb the autonomic balance that keeps you steady upright.⁴

These are single-study leads rather than settled mechanisms, and both come from small samples that have not been reproduced at scale. They matter for a practical reason: if low serotonin or a platelet quirk is driving one person's symptoms, the treatment that helps them may differ from the one that helps a person whose main problem is low blood volume. That is the recurring lesson of orthostatic intolerance. It is not one disease with one fix but a shared symptom fed by several different routes, which is why a treatment that transforms one patient can do nothing for the next and why matching the approach to the likely mechanism matters more here than in many conditions.

thinpossible subgroups

First, fill the tank

The most useful interventions are the least dramatic. Increasing salt and fluid intake expands blood volume, compression garments over the legs and abdomen stop blood from pooling, raising the head of the bed slightly trains the system overnight, and rebuilding fitness with recumbent exercise like a rowing machine avoids the upright posture that triggers symptoms. A systematic review of post-COVID autonomic problems places these supportive measures first.⁵

Patients consistently rate these basics among the things that help most, which is worth saying plainly because they are cheap, safe, and available today. They are not a cure, and they ask for steady habit rather than a one-time fix, but they are the foundation every drug is added on top of, not a fallback for when drugs fail.

salt, fluids, compression: first-linehighest patient-rated benefitstandard supportive care

The surrogate-versus-symptom trap

Here is the single most important thing to understand about treating this. A racing pulse is easy to measure and easy to lower with a heart-rate drug, so a drug that brings the number down can look like success. But the number is a stand-in, a surrogate. What you actually care about is whether the dizziness and fog lift, and that is a different question.

The large randomized trials in this area were built precisely around that distinction. Their main yardstick is the change in orthostatic-intolerance symptoms, not the heart rate.⁷ The honest current read is that lowering the pulse has not delivered the symptom relief its effect on the number might suggest, which is exactly why the supportive basics, not the pulse-slowing pill, remain the first move.⁵

rate-lowering is a surrogate, not the goalsymptom benefit not establishedsymptom-primary trials underway

When drugs are added

If the basics are not enough, several medicines are used off-label and under supervision. A volume-retaining steroid has Cochrane-reviewed evidence for orthostatic symptoms.⁶ A vessel-tightening drug, midodrine, produces a high rate of symptom response in practice, though its formal evidence base is weak and largely borrowed from general orthostatic intolerance rather than the post-COVID kind.

Other agents, including pyridostigmine, have not clearly beaten simpler options in head-to-head use. The pattern across all of them is the same: modest, individual, and worth a careful trial only after the volume and compression foundation is in place. None is approved specifically for post-COVID orthostatic intolerance, so each is a considered experiment, not a settled prescription.

fludrocortisone: review-backedmidodrine: thin, borrowed dataall off-label, supervised

The bundle that may beat the pill

A hopeful theme is emerging from the same trials. Coordinated nonpharmacologic care, a structured program that bundles the salt and fluid plan, compression, paced reconditioning, and patient education into supervised, joined-up support, is being tested directly against medication.⁷

The early signal is that organized supportive care holds its own and may do better than the drug arm. That fits everything else on this page: the problem is a supply-and-control failure that responds best to steady, layered management rather than a single pharmacological lever. It also puts real tools in your hands now, while the drug questions are still being settled.

coordinated supportive careemerging, well-founded direction

What this means for you

If standing makes you dizzy and sitting fixes it, the most useful single fact is that the cheapest, safest steps are also the ones that help most. Raise salt and fluids unless a clinician has told you otherwise, wear compression over the legs and belly, and rebuild fitness lying down rather than upright. These are the foundation, not the fallback, and they are available to you today.

The second useful fact protects you from a common trap. A drug that slows your pulse is treating a number, not your dizziness, and on the symptom measures that matter the pulse-slowing pills have not delivered. So if a clinician reaches for one early, it is fair to ask whether the supportive basics have been given a real trial first, and whether a coordinated, joined-up supportive program is available to you. Keep any medication under supervision, since several can shift your blood pressure.

References

Each reference links to the source on PubMed, PMC, or the publisher.

1. Blood volume perturbations in the postural tachycardia syndrome. American Journal of the Medical Sciences, 2007.
2. Blood volume deficit in POTS assessed by a semiautomated carbon monoxide rebreathing method. 2025.
3. Postural orthostatic tachycardia syndrome is associated with platelet storage pool deficiency. Medicine, 2017.
4. Serotonin reduction in post-acute sequelae of viral infection. Cell, 2023.
5. Postural orthostatic tachycardia syndrome after COVID-19: a systematic review of therapeutics. 2023.
6. Fludrocortisone for orthostatic intolerance (Cochrane review). 2021.
7. Design and rationale of RECOVER-AUTONOMIC: a randomized trial of ivabradine, IVIG, and coordinated nonpharmacologic care for long COVID POTS, with symptom change as the primary endpoint. American Heart Journal, 2026.